As biotech confidence returns and deal activity accelerates, companies have an opportunity to position themselves for the next phase of growth. In a new BioPharma Dive article, Deepali Suri, President of ICON Biotech, s...
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
Operational discipline is a critical determinant of clinical utility for neurologic monoclonal antibodies
In neurologic mAb development, the therapies that reach patients will be those designed not only to work, but to be delivered. Discover how operational discipline is emerging as a key differentiator in translating scientific advances into clinical utility.
-
ICON partners with Anthropic in multi-year collaboration to deploy Claude's frontier AI across the clinical trial lifecycle
ICON's multi-year collaboration with Anthropic will bring Claude's AI capabilities to key clinical development workflows, helping accelerate innovation and enhance the delivery of clinical trials worldwide.
-
ICON to deploy Claude AI across clinical trial lifecycle
ICON is deploying Claude AI across its organisation and clinical development operations, combining advanced AI capabilities with deep clinical expertise to improve efficiency, productivity and decision-making.
-
ICON partners with Anthropic to integrate Claude AI in clinical trials
ICON has partnered with Anthropic to integrate Claude's frontier AI capabilities into the clinical trial lifecycle through its secure Orbis platform, advancing study planning, trial intelligence and protocol optimisation.
-
What medtech makers need to know about the EU’s new packaging rules
The European PPWR comes into force in August 2026. ICON's contributing authors provide their perspective on the impact and what Sponsors need to consider as a result of the new rules for Med Devices.
-
From confidence to capital: Positioning biotech for the next growth cycle
How can biotechs position themselves for the next growth cycle? Deepali Suri shares insights on investor readiness, AI, global development strategies and emerging opportunities across biotech.
-
Establishing ctDNA as a validated primary surrogate endpoint
Unlocking faster paths to precision oncology. This article examines the promise of ctDNA as a validated surrogate endpoint and what it could mean for accelerating drug development and expanding patient access to innovative cancer therapies.
-
Why Europe, not America, may be Chinese sponsors’ smartest move
As Chinese sponsors expand globally, Europe offers a stable, science-driven regulatory environment and broad market access across the region. Planning for EMA requirements from the outset helps accelerate approvals, minimise costly study adaptations and support long-term commercial success.
-
Real-World Evidence in transition: CRO adaptation to the European Health Data Space framework
This article explores how the European Health Data Space (EHDS) is transforming real-world evidence generation by shifting CROs from data custodians to regulated data users operating within secure, interoperable environments, creating new opportunities for pan-European research while requiring greater investment in compliance, data standardisation and methodological rigour.
-
Chinese drugmakers with big ambitions struggle to recruit staff for global expansion
China's rapid rise as a hub for testing experimental, next-generation medicines is outpacing the industry's ability to build the workforce needed to take those products global.
